HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: zanolimumab, a human monoclonal antibody targeted against CD4.

Abstract
Merck Serono SA, under license from Genmab A/S and Medarex Inc, is developing zanolimumab, a human mAb targeted against CD4, for the potential treatment of cutaneous (CTCL) and noncutaneous (NCTCL) T-cell lymphomas. Zanolimumab is currently undergoing phase III clinical trials for CTCL and phase II clinical trials for NCTCL.
AuthorsChalid Assaf, Wolfram Sterry
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 2 Pg. 197-203 (Apr 2007) ISSN: 1464-8431 [Print] England
PMID17458175 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD4 Antigens
  • zanolimumab
Topics
  • Antibodies, Monoclonal (adverse effects, pharmacokinetics, pharmacology)
  • Antibodies, Monoclonal, Humanized
  • CD4 Antigens (immunology)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Contraindications
  • Drug Evaluation, Preclinical
  • Humans
  • Patents as Topic
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: